ArticleAmerican journal of hypertension2018
Angiotensin Receptor Expression and Vascular Endothelial Dysfunction in Obstructive Sleep Apnea.
Article in American journal of hypertension, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04021550 (Combined Treatment of Angiotensin Receptor Blocker and Antioxidant Supplementation as a Novel Adjunctive Therapy for 24-hour Blood Pressure Improvement in Obstructive Sleep Apnea), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Combined Treatment of Angiotensin Receptor Blocker and Antioxidant Supplementation as a Novel Adjunctive Therapy for 24-hour Blood Pressure Improvement in Obstructive Sleep Apnea
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Effects of losartan and allopurinol on cardiorespiratory regulation in obstructive sleep apnoea.Experimental physiology · 2018Trial
- Improving the cardiovascular outcomes of obstructive sleep apnea: Towards more precise hypoxia-based models of disease severity.Current sleep medicine reports · 2025Article
- Unraveling the Complexities of Oxidative Stress and Inflammation Biomarkers in Obstructive Sleep Apnea Syndrome: A Comprehensive Review.Life (Basel, Switzerland) · 2024Review
- Angiotensin II type 1 receptor localizes at the blood-bile barrier in humans and pigs.Histochemistry and cell biology · 2022Article
- Endothelial Dysfunction and Cardiovascular Risk in Obstructive Sleep Apnea: A Review Article.Life (Basel, Switzerland) · 2022Review
- Pathways of Microcirculatory Endothelial Dysfunction in Obstructive Sleep Apnea: A Comprehensive Ex Vivo Evaluation in Human Tissue.American journal of hypertension · 2022Article
- Sleep apnea, coronary artery calcium density, and cardiovascular events: results from the Multi-Ethnic Study of Atherosclerosis.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2021Article
- Cardiovascular Disorders Triggered by Obstructive Sleep Apnea-A Focus on Endothelium and Blood Components.International journal of molecular sciences · 2021Review
- Targeting subclinical organ damage in obstructive sleep apnea: a narrative review.Journal of human hypertension · 2021Review
- Review
- Putative contributions of circadian clock and sleep in the context of SARS-CoV-2 infection.The European respiratory journal · 2020Article
- Could Adjunctive Pharmacology Mitigate Cardiovascular Consequences of Obstructive Sleep Apnea?American journal of respiratory and critical care medicine · 2019Article
- CARDIOVASCULAR COMPLICATIONS OF ACROMEGALY.Acta endocrinologica (Bucharest, Romania : 2005)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundObstructive sleep apnea (OSA) is associated with vascular endothelial dysfunction (VED) in otherwise healthy patients. The role of renin-angiotensin system (RAS) in the OSA induced VED is not well understood.
methodsRecently diagnosed OSA patients with very low cardiovascular disease (CVD) risk (Framingham score <5%) were studied at diagnosis and after 12 weeks of verified continuous positive airway pressure (CPAP) therapy. Participants underwent biopsy of gluteal subcutaneous tissue at baseline and after CPAP. Microcirculatory endothelial expression of angiotensin receptors type-1 (AT-1) and type-2 (AT-2) was measured in the subcutaneous tissue using quantitative confocal microscopy techniques. The ex-vivo effect of AT-1 receptor blockade (ARB) on endothelial superoxide production was also measured before and after CPAP treatment.
resultsIn OSA patients (n = 11), microcirculatory endothelial AT1 expression decreased from 873 (200) (fluorescence units) at baseline to 393 (59) units after 12 weeks of CPAP (P = 0.02). AT2 expression did not decrease significantly in these patients (479 (75) to 329 (58) post CPAP (P = 0.08)). The ex-vivo addition of the losartan to the microcirculatory endothelium resulted in decreased superoxide expression in the vascular walls from 14.2 (2.2) units to 4.2 (0.8) P < 0.001; while it had no effect on post-CPAP patient tissue (P = 0.64).
conclusionsIn OSA patients with no to minimal CVD risk, VED is associated with upregulation of AT-1 expression that is reversible with CPAP. Endothelial oxidative stress was reversible with ARB. RAS activation may play an important role in the development of early CVD risk in OSA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.